Annor, DNP, AGPCNP-BC , known as Dr
So someone can have a strong family history, metabolic dysfunction, discordantly high apoB, early scans suggesting disease, and a high risk cumulative exposure picture and still look "low risk" in a short-term model due to their age
Significant weight loss continues progressively, with clinical trials showing an average of 68% weight reduction by week 16 and approximately 15% at 68 weeks on the full maintenance dose
In an earlier cohort study involving 52 -thalassemia patients with HF, who received chelation therapy in combination with standard anti-heart failure treatment had a survival rate of approximately 50% over a 5-year period, comparable to other HF patients (194)
Review concurrent medications and medical history with your clinician